Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
Meng X, Chin PS, Hashmonay R, Zahur Islam M, Cutter G
Contemp Clin Trials. 2014 Dec 26. PMID: 25545026.Abstract